Indaptus Therapeutics (NASDAQ:INDP) Trading 1.5% Higher

Indaptus Therapeutics, Inc. (NASDAQ:INDP) rose 1.5% on Wednesday . The stock traded as high as $2.09 and last traded at $2.08. Approximately 5,627 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 63,845 shares. The stock had previously closed at $2.05.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Indaptus Therapeutics in a research report on Monday, April 15th.

Indaptus Therapeutics Stock Up 1.5 %

The business’s 50 day simple moving average is $2.26 and its 200-day simple moving average is $2.06. The stock has a market capitalization of $17.76 million, a price-to-earnings ratio of -1.13 and a beta of 1.28.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. On average, analysts expect that Indaptus Therapeutics, Inc. will post -1.83 earnings per share for the current year.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.